When was Particella founded?

Particella was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Particella located?

Particella is headquartered in San Francisco, United States.

Who is the current CEO of Particella?

Mubhij Ahmad of Particella. They have also founded 1 company.

How many employees does Particella have?

As of Sep 30, 2026, the latest employee count at Particella is 6.

Is Particella a funded company?

Particella is a funded company, having raised a total of $7.35M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 31, 2017.

When was the latest funding round of Particella?

Particella's latest funding was a $***** Series A round on Apr 01, 2022, with participation from 0 investor. Its primary sector is Gastroenterology. In United States, the Gastroenterology sector has seen $957M in funding in 2026 to date.

Where does Particella rank among its competitors?

Particella ranks 788th amongst 2610 active competitors, of which 873 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Particella?

Particella's top competitors include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Particella - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene therapies for gastrointestinal diseases.It provides mRNA and other nucleic acid-based drugs to the GI cells via oral lipid nanoparticle technology to combat gastrointestinal and systemic illnesses.

Website: particella.bio
Social

Key Metrics

Founded Year

2016

Location

San Francisco, United States

Stage

Series A

Total Funding

$7.35M in 4 rounds

Latest Funding Round

Series A, Apr 01, 2022, $*****

Investors

SOSV & 8 more

Ranked

788^th among 2610 active competitors

Employee Count

6 as on Sep 30, 2026

Similar Companies

Strand Therapeutics & 196 more

View Particella's full profile

Particella is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DNA LITE THERAPEUTICS, INC. CIN: 811554862 , United States, Active	Dec 31, 1999	-	4 (As on Dec 31, 2024)	-

Particella has raised a total funding of $7.35M over 4 rounds. Its first funding round was on May 31, 2017. Particella has 9 institutional investors.

Here is the list of recent funding rounds of Particella:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2022	7111494	Series A	1353704	9796063	1170633	2925627
Feb 01, 2019	6022247	Grant (prize money)	9414062	8144641	1483104	National Science Foundation
Aug 08, 2018	3171721	Seed	8991965	5195389	Blue Bear Ventures & 4 more	9619819

Access funding benchmarks and valuations. Sign up today!

View details of Particella's funding rounds and investors

The founders of Particella are Timothy Day and Mubhij Ahmad. Mubhij Ahmad is the CEO of Particella.

Here are the details of Particella's key team members:

Timothy Day: Co-Founder of Particella. They serve on the board of 1 company.
Mubhij Ahmad: Co-Founder & CEO of Particella.
Contact Info: 1 email address

View details of Particella's Founder profiles and Board Members

Particella's employee count trend

Particella has 6 employees as of Sep 26. Here is Particella's employee count trend over the years:

Uncover Particella's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Particella include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of Particella, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
3rd	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
4th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
6th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
7th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
8th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
10th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
788th	Particella 2016, San Francisco (United States), Series A	Developer of gene therapies for gastrointestinal diseases	$7.35M	SOSV, Berkeley Catalyst Fund & 7 others	41/100